The aim of the current study is to measure the effect of melatonin as adjunct therapy on oxidative stress, inflammatory markers and clinical outcome in type 2 diabetic patients with diabetic peripheral neuropathy.
Patients aged 40-75 years diagnosed with type 2 DM.
Diabetes duration at least 1 year.
Patients diagnosed with diabetic peripheral neuropathy.
Stable antidiabetic medication for at least 1 month before enrollment and during the trial
Patients with autoimmune disorders (such as lupus and rheumatoid arthritis), thyroid diseases, peripheral arterial disease and cancer patients.
Patients with severe kidney or liver dysfunction.
Patients diagnosed with neurodegenerative diseases.
Active infection.